Company Profile
MoonLake Immunotherapeutics Stock Price, News & Analysis
- Ticker:
- MLTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Switzerland
Stock performance
18.03 USD (+2.74%)
Close
Last updated: August 6, 2026
1.32B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, MLTX closed up 2.74% at $18.03. No new same-company headline was identified in the current news window.
Company overview
Nanobody-Based Immunology
MoonLake Immunotherapeutics develops therapies for inflammatory diseases using Nanobody technology. Nanobodies are compact antibody-derived domains that may provide strong tissue penetration and flexible molecular design.
Sonelokimab
Sonelokimab is a trivalent Nanobody designed to inhibit IL-17A and IL-17F while binding albumin. The candidate is being advanced as a potential treatment for hidradenitis suppurativa and other inflammatory conditions.
Registrational Hidradenitis Program
The MIRA and VELA studies form the clinical package for a planned U.S. application in hidradenitis suppurativa, including data in adults and adolescents.
Future catalysts
BLA submission for sonelokimab in hidradenitis suppurativa by the end of September 2026.
FDA filing acceptance and a decision on Priority Review designation by the end of November 2026.
Recent news
- 01
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
Source: MoonLake Immunotherapeutics
- 02
MoonLake Immunotherapeutics Announces Proposed Public Offering
Source: MoonLake Immunotherapeutics
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MoonLake Immunotherapeutics (MLTX)?
MoonLake Immunotherapeutics (MLTX) most recently closed at 18.03 USD, a +2.74% move versus the previous session.
What is the market cap of MoonLake Immunotherapeutics (MLTX)?
MoonLake Immunotherapeutics currently has a market capitalization of 1.32B USD on BioPharmSignal.
What does MoonLake Immunotherapeutics do?
Nanobody-Based Immunology MoonLake Immunotherapeutics develops therapies for inflammatory diseases using Nanobody technology. Nanobodies are compact antibody-derived domains that may provide strong tissue penetration and flexible molecular design. Sonelokimab Sonelokimab is a trivalent Nanobody designed to inhibit IL-17A and IL-17F while binding albumin....
On which exchange is MLTX stock listed?
MoonLake Immunotherapeutics (MLTX) is associated with NASDAQ, Switzerland, Biopharma.
What is IL-17A?
Sonelokimab Sonelokimab is a trivalent Nanobody designed to inhibit IL-17A and IL-17F while binding albumin.
Which conditions is MoonLake Immunotherapeutics targeting with IL-17A?
MoonLake Immunotherapeutics is associated with immunology based on its company overview and current catalyst commentary.
How does MoonLake Immunotherapeutics describe recent progress with IL-17A?
BLA submission for sonelokimab in hidradenitis suppurativa by the end of September 2026. FDA filing acceptance and a decision on Priority Review designation by the end of November 2026.
What is IL-17F?
Sonelokimab Sonelokimab is a trivalent Nanobody designed to inhibit IL-17A and IL-17F while binding albumin.